安息香与华法林的草药-药物相互作用:分子基础与机制
本研究探讨安息香对细胞色素P450酶的抑制及其与华法林的相互作用。体外实验显示安息香提取物强烈抑制CYP3A并中度抑制其他六种CYP,且抑制华法林10-羟化。大鼠体内实验表明,安息香(100 mg/kg)与华法林(2 mg/kg)合用时,华法林血浆半衰期延长2.3倍,AUC(0-inf)增加2.7倍。安息香中的五环三萜酸类成分是强CYP3A抑制剂,其中齐墩果酸为竞争性抑制剂。
要点
- 安息香提取物强烈抑制CYP3A,并中度抑制其他六种CYP。
- 大鼠合用安息香(100 mg/kg)使华法林半衰期延长2.3倍、AUC增加2.7倍。
- 安息香中五环三萜酸类成分是CYP3A抑制剂,齐墩果酸为竞争性抑制。
核心结论
- 安息香及其所含五环三萜酸通过抑制CYP3A强烈调节华法林的药代动力学行为。
研究设计与样本
- 体外采用人肝微粒体 assay 抑制效应,体内采用大鼠研究安息香与华法林的药代动力学相互作用。
主要发现
- 安息香提取物体外强烈抑制人CYP3A,中度抑制其他六种受试人CYP,并有效抑制人和大鼠肝微粒体中华法林的10-羟化。
- 大鼠体内,安息香(100 mg/kg)与华法林(2 mg/kg)合用相比单用华法林,华法林血浆半衰期延长2.3倍,AUC(0-inf)增加2.7倍。
- 安息香中五个五环三萜酸(epibetulinic acid、betulinic acid、betulonic acid、oleanonic acid 和 maslinic acid)为强CYP3A抑制剂,oleanonic acid 对CYP3A介导的睾酮6β-羟化为竞争性抑制。
关键数值与推荐
- 大鼠体内,安息香100 mg/kg合用华法林2 mg/kg时,华法林半衰期延长2.3倍,AUC(0-inf)增加2.7倍。
临床怎么用
- 中医及中西医结合医生应警惕安息香或含安息香制剂与华法林合用时可能增加出血风险,建议监测凝血指标。
局限性
- 相互作用数据来自大鼠模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Styrax, one of the most famous folk medicines, has been frequently used for the treatment of cardiovascular diseases and skin problems in Asia and Africa. It is unclear whether Styrax or Styrax-related herbal medicines may trigger clinically relevant herb-drug interactions. PURPOSE: This study was carried out to investigate the inhibitory effects of Styrax on human cytochrome P450 enzymes (CYPs) and to clarify whether this herb may modulate the pharmacokinetic behavior of the CYP-substrate drug warfarin when co-administered. STUDY DESIGN: The inhibitory effects of Styrax on CYPs were assayed in human liver microsomes (HLM), while the pharmacokinetic interactions between Styrax and warfarin were investigated in rats. The bioactive constituents in Styrax with strong CYP3A inhibitory activity were identified and their inhibitory mechanisms were carefully investigated. METHODS: The inhibitory effects of Styrax on human CYPs were assayed in vitro, while the pharmacokinetic interactions between Styrax and warfarin were studied in rats. Fingerprinting analysis of Styrax coupled with LC-TOF-MS/MS profiling and CYP inhibition assays were used to identify the constituents with strong CYP3A inhibitory activity. The inhibitory mechanism of oleanonic acid (the most potent CYP3A inhibitor occurring in Styrax) against CYP3A4 was investigated by a panel of inhibition kinetics analyses and in silico analysis. RESULTS: In vitro assays demonstrated that Styrax extract strongly inhibited human CYP3A and moderately inhibited six other tested human CYPs, as well as potently inhibited warfarin 10-hydroxylation in liver microsomes from both humans and rats. In vivo assays demonstrated that compared with warfarin given individually in rats, Styrax (100 mg/kg) significantly prolonged the plasma half-life of warfarin by 2.3-fold and increased the AUC(0-inf) of warfarin by 2.7-fold when this herb was co-administrated with warfarin (2 mg/kg) in rats. Two LC fractions were found with strong CYP3A inhibitory activity and the major constituents in these fractions were characterized by LC-TOF-MS/MS. Five pentacyclic triterpenoid acids (including epibetulinic acid, betulinic acid, betulonic acid, oleanonic acid and maslinic acid) present in Styrax were potent CYP3A inhibitors, and oleanonic acid was a competitive inhibitor against CYP3A-mediated testosterone 6β-hydroxylation. CONCLUSION: Styrax and the pentacyclic triterpenoid acids occurring in this herb strongly modulate the pharmacokinetic behavior of warfarin via inhibition of CYP3A.
引用
- Zhang F, Huang J, He RJ, et al. Herb-drug interaction between Styrax and warfarin: Molecular basis and mechanism. Phytomedicine. 2020. PMID: 32739573. doi:10.1016/j.phymed.2020.153287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。